Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168181 | 0.80 | KMT2A (0.56) | RAB9AKMT2AALDH1A1 | |
| SCHEMBL25120310 | 0.79 | RAB9A (0.48) | RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL13107095 | 0.76 | ALDH1A1 (0.48) | RAB9ANPC1TSHRALDH1A1LMNA | |
| SCHEMBL13096994 | 0.72 | CHRNB4 (0.48) | RAB9ANPC1CNR1CNR2 | |
| SCHEMBL1168210 | 0.71 | ALDH1A1 (0.42) | RAB9ANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL13106486 | 0.71 | ALDH1A1 (0.48) | RAB9ANPC1TSHRALDH1A1LMNA | |
| SCHEMBL4681513 | 0.70 | ALDH1A1 (0.49) | RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL21556183 | 0.69 | HSD17B10 (0.58) | RAB9ANPC1KMT2ATSHRALDH1A1 | |
| SCHEMBL12877576 | 0.68 | SLC2A1 (0.45) | RAB9ANPC1SLC2A1TSHRL3MBTL1 | |
| SCHEMBL8985604 | 0.68 | MAOB (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | RAB9A 2384/4885NPC1 317/4885SLC2A1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.